Your browser doesn't support javascript.
loading
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
Darlow, Christopher A; Docobo-Perez, Fernando; Farrington, Nicola; Johnson, Adam; McEntee, Laura; Unsworth, Jennifer; Jimenez-Valverde, Ana; Gastine, Silke; Kolamunnage-Dona, Ruwanthi; de Costa, Renata M A; Ellis, Sally; Franceschi, François; Standing, Joseph F; Sharland, Mike; Neely, Michael; Piddock, Laura; Das, Shampa; Hope, William.
Afiliación
  • Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Docobo-Perez F; Departamento de Microbiología, Universidad de Sevilla, Seville, Spain.
  • Farrington N; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Johnson A; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • McEntee L; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Unsworth J; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Jimenez-Valverde A; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Gastine S; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • Kolamunnage-Dona R; Department of Health Data Science, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • de Costa RMA; Global Antibiotic Research and Development Partnership, Geneva, Switzerland.
  • Ellis S; Global Antibiotic Research and Development Partnership, Geneva, Switzerland.
  • Franceschi F; Global Antibiotic Research and Development Partnership, Geneva, Switzerland.
  • Standing JF; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • Sharland M; Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.
  • Neely M; Children's Hospital Los Angeles and the Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Piddock L; Global Antibiotic Research and Development Partnership, Geneva, Switzerland.
  • Das S; Antimicrobials Research Group, School of Immunity and Infection, Institute for Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
  • Hope W; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
Antimicrob Agents Chemother ; 65(7): e0029321, 2021 06 17.
Article en En | MEDLINE | ID: mdl-33972238
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sepsis Neonatal / Fosfomicina / Antibacterianos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans / Newborn Idioma: En Revista: Antimicrob Agents Chemother Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sepsis Neonatal / Fosfomicina / Antibacterianos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans / Newborn Idioma: En Revista: Antimicrob Agents Chemother Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos